"Drug"

Many lung cancer patients will be detected by genetic testing to carry an EGFR mutation, and these patients can often control their tumours with EGFR-targeted drugs. Although targeted drugs are effective and have fewer side effects than chemotherapy, resistance to them inevitably occurs, after which they no longer work.

Pancreatic cancer is known to be a highly fatal and incurable type of cancer known as the "king of cancers". Currently, the only possible cure for pancreatic cancer is the complete surgical removal of the tumour tissue. Once the cancer has spread beyond the pancreatic organ, the patient's treatment options are very limited.

Bile duct cancer is a rare but highly malignant tumour that occurs in the human bile duct system and has long had a poor prognosis. Now, researchers at University College London and University College London Hospitals, in an international multi-centre trial, have identified potentially good treatments that may radically improve the lives of some patients with bile duct cancer.

A new study has found that Istradefylline, a drug already approved to treat Parkinson's disease, not only reduces the toxicity associated with the chemotherapy drug cisplatin, but also boosts its cancer-fighting power, promising a potential treatment to reduce the side effects of chemotherapy.

Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!

A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!

The impact of AlphaFold on protein structure prediction has been transformative.

Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.

The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.

Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.